anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
•
     In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
•
     OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications (4) and Warnings and Precautions (5.1)].
The invention relates to a traditional Chinese medicine for treating goat oral cavity ulceration and a preparation method thereof. The traditional Chinese medicine for treating goat oral cavity ulceration is prepared from the following main raw materials in parts by weight: 10-20 parts of dragon blood, 20-30 parts of frankincense and 20-30 parts of myrrh. The preparation method comprises the following steps: drying the dragon blood, the frankincense and the myrrh according to a regular way and grinding the raw materials into powder respectively; mixing the powder in proportion and preserving in a sealing manner. The traditional Chinese medicine for treating goat oral cavity ulceration is prepared from the dragon blood, the frankincense and the myrrh according to the modern traditional Chinese medicine matching. The dragon blood can dissipate decoction and relieve pain; the frankincense can relieve pain and remove toxicity; the myrrh can diminish swelling and promote granulation. The traditional Chinese medicine can directly function on a wounded part of the oral cavity of a goat to play the role of relieving pain and prompting granulation, dissipating decoction and relieving pain. The provided medicine is the traditional Chinese medicine with no toxicity, wide source of raw materials, low cost, capability of curing goat oral cavity ulceration efficiently, short treatment course, fast effect and difficulty in relapse; the preparation method is simple, consumes no energy, and generates no gas and wastewater to pollute the environment.
The long-term effects of a single episode of acute kidney injury (AKI) induced by bilateral ischemia-reperfusion injury (BIRI) on kidney lymphatic dynamics are not known. The purpose of this study was to determine if alterations in kidney lymphatics are sustained in the long term and how they relate to inflammation and injury. Mice underwent BIRI as a model of AKI and were followed up to 9 mo. Although kidney function markers normalized following initial injury, histological analysis revealed sustained tissue damage and inflammation for up to 9 mo. Transcriptional analysis showed both acute and late-stage lymphangiogenesis, supported by increased expression of lymphatic markers, with unique signatures at each phase. Expression of Ccl21a was distinctly upregulated during late-stage lymphangiogenesis. Three-dimensional tissue cytometry confirmed increased lymphatic vessel abundance, particularly in the renal cortex, at early and late timepoints postinjury. In addition, the study identified the formation of tertiary lymphoid structures composed of CCR7+ lymphocytes and observed changes in immune cell composition over time, suggesting a complex and dynamic response to AKI involving tissue remodeling and immune cell involvement. This study provides new insights into the role of lymphatics in the progression of AKI to chronic kidney disease.NEW & NOTEWORTHY Here, we perform the first, comprehensive study of long-term lymphatic dynamics following a single acute kidney injury (AKI) event. Using improved three-dimensional image analysis and an expanded panel of transcriptional markers, we identify multiple stages of lymphatic responses with distinct transcriptional signatures, associations with the immune microenvironment, and collagen deposition. This research advances kidney lymphatic biology, emphasizing the significance of longitudinal studies in understanding AKI and the transition to chronic kidney disease.
Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.
INTRODUCTION: Cardiovascular disease is an important cause of death among patients with chronic kidney disease (CKD). Valve calcification is a predictor of cardiovascular mortality and coronary artery disease.
OBJECTIVE: To assess heart valve disease frequency, associated factors, and progression in CKD patients.
METHODS: We conducted a retrospective study on 291 CKD patients at Hospital das Clínicas de Pernambuco. Inclusion criteria were age ≥ 18 with CKD and valve disease, while those on conservative management or with missing data were excluded. Clinical and laboratory variables were compared, and patients were categorized by dialysis duration (<5 years; 5-10 years; >10 years). Statistical tests, including chi-square, Fisher's exact, ANOVA, and Kruskal-Wallis, were employed as needed. Simple and multivariate binary regression models were used to analyze valve disease associations with dialysis duration. Significance was defined as p < 0.05.
RESULTS: Mitral valve disease was present in 82.5% (240) of patients, followed by aortic valve disease (65.6%; 86). Over time, 106 (36.4%) patients developed valve disease. No significant association was found between aortic, pulmonary, mitral, or tricuspid valve disease and dialysis duration. Secondary hyperparathyroidism was the sole statistically significant factor for mitral valve disease in the regression model (OR 2.59 [95% CI: 1.09-6.18]; p = 0.031).
CONCLUSION: CKD patients on renal replacement therapy exhibit a high frequency of valve disease, particularly mitral and aortic valve disease. However, no link was established between dialysis duration and valve disease occurrence or progression.
The invention belongs to the medical field and relates to the application of vitamin pharmaceuticals and health care, particularly the prevention and health-care function of pteroylglutamic acid for offspring glycometabolism disorder caused by caused by environmental endocrine disruptors (EED) during pregnancy. The pteroylglutamic acid intervention experiment is conducted on female SD rats during pregnancy and during lactation by utilizing animal experimental models. It has been determined that, pteroylglutamic acid can prevent the high morbidity rate of type I diabetes caused by insulin structure and function abnormity under the effect of typical EEDs. The result shows that, the pteroylglutamic acid supplementation during pregnancy can prevent the high morbidity rate of offspring glycometabolism disorder caused by EEDs. The pteroylglutamic acid is harmless to human bodies within the control dosage range and can be safely used. When the pteroylglutamic acid is added in health-care products or used as a food intensifying agent to be administered orally, the pteroylglutamic acid can prevent the offspring glycometabolism disorder caused by EEDs.
The use of a cell-permeant molecular probe to assay the presence, and monitor the production, of the reactive oxygen species, superoxide, in red blood cells (RBCs) is described. The assay is performed using electron paramagnetic resonance (EPR) spectroscopy and a cell-permeant hydroxylamine spin trap. The cell-permeant molecular probe is not detected or quantifiable by EPR in its reduced form. However, upon entering the RBCs, the probe is oxidized by reacting with superoxide to yield a stable nitroxide radical that is detected and quantified using EPR. Our studies indicate that superoxide production is consistent with RBC metabolism that predicts lipid oxidation, membrane injury and poor post-transfusion performance. Therefore, measurement of reactive oxygen species can be used as an indicator of RBC quality at the time of donation and after storage.
NEW MATERIAL:A compound shown by formula I (R1 is OH or 1-6C acyloxy; R2 is H or lower alkyl; R3 is lower alkyl; X and Y are H or halogen; Z is O or S; wavy line is in alpha or beta steric configuration; broken line between the 1 and 2 positions may be double bond). EXAMPLE:21-(3-Ethoxy-1,3-dioxopropoxy)-9-fluoro-11,17-dihydroxy--16beta- methylpregna-1,4-diene-3,20-dione. USE:An antiinflammatory drug showing highly antiinflammatory effects with an extremely small amount. PREPARATION:A steroid compound shown by formula II is allowed to react with 1-3 equivalents, based on the compound, of an acid chloride of malonic acid monoester shown by formula III in the presence of a basic catalyst (e.g. pyridine or triethylamine) in a solvent (e.g. methylene chloride) at -20 to 10 deg.C for 1-2 hours while stirring.
PURPOSE:A cosmetic, e.g. a foundation, face powder or bady powder, containing an alkyl phosphate and powder therefore, having water repellency and light extensibility on the skin, scarcely causing makeup disorder, and capable of improving the moist feeling. CONSTITUTION:A cosmetic containing an alkyl phosphate of the formula (R1 and R2 are H ro 1-36C alkyl; R3 is 1-36C alkyl) and powder therefor. The cosmetic has powerful water repellency without dry feeling, improves remarkably the smoothness and moist feeling on the skin, and has good moldability in press molding. Inorganic powder, e.g. talc, titanium oxide, mica coated with iron oxide, etc. may be preferred as the powder for the cosmetic. The above-mentioned cosmetic is preferably produced by dissolving the alkyl phosphite in benzene, etc. under heating and adding the powder for the cosmetic to the resultant solution, and stirring the resultant mixture to coat the powder with the alkyl phosphite.
Quality of Life (QOL) was measured during both the diagnostic study [see Clinical Studies (14.1)] and the ablation of thyroid remnant study [see Clinical Studies (14.2)] using the SF-36 Health Survey, a standardized, patient-administered instrument assessing QOL across eight domains measuring both physical and mental functioning. In the diagnostic study and in the remnant ablation study, following THYROGEN administration, little change from baseline was observed in any of the eight QOL domains of the SF-36. Following thyroid hormone withdrawal in the diagnostic study, statistically significant negative changes were noted in all eight QOL domains of the SF-36. The difference between treatment groups was statistically significant (p<0.0001) for all eight QOL domains, favoring THYROGEN over thyroid hormone withdrawal (Figure 2). In the remnant ablation study, following thyroid hormone withdrawal, statistically significant negative changes were noted in five of the eight QOL domains (physical functioning, role physical, vitality, social functioning and mental health).

Figure 2: SF-36 Health Survey Results Quality of Life Domains Diagnostic Indication
Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in viral growth characteristics, attenuation, plaque size, and/or a change in cytopathogenicity, among other novel phenotypes. A variety of additional mutations and nucleotide modifications are provided within the C, D and/or V ORF(s) deletion or ablation mutant PIV of the invention to yield desired phenotypic and structural effects.
The risks of using quetiapine in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be avoided while taking quetiapine.

Because of its potential for inducing hypotension, quetiapine may enhance the effects of certain antihypertensive agents.

Quetiapine may antagonize the effects of levodopa and dopamine agonists.

The use of quetiapine should be avoided in combination with drugs known to increase QT interval, and caution should be exercised when quetiapine is used in combination with drugs known to cause electrolyte imbalance [see Warnings and Precautions (5.12)].

There have been literature reports suggesting false positive results in urine enzyme immunoassays for methadone and tricyclic antidepressants in patients who have taken quetiapine. Caution should be exercised in the interpretation of positive urine drug screen results for these drugs, and confirmation by alternative analytical technique (e.g. chromatographic methods) should be considered.
Quetiapine is an atypical antipsychotic belonging to a chemical class, the dibenzothiazepine derivatives. The chemical designation is 2-[2-(4-dibenzo [b,f] [1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fumarate (2:1) (salt). It is present in tablets as the fumarate salt. All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt. Its molecular formula is C42H50N6O4S2•C4H4O4 and it has a molecular weight of 883.10 (fumarate salt). The structural formula is:

    

Quetiapine fumarate USP is a white to off-white powder which is moderately soluble in water.

Quetiapine Tablets USP are available for oral administration containing either 25 mg, 50 mg, 100 mg, 200 mg, 300 mg or 400 mg of quetiapine fumarate. Each 25 mg tablet contains the following inactive ingredients: lactose, magnesium stearate, microcrystalline cellulose, povidone, purified water and sodium starch glycolate.

The 50 mg, 100 mg, 200 mg, 300 mg and 400 mg tablets contain the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, povidone, purified water and sodium starch glycolate.

Each 25 mg tablet contains 28.75 mg of quetiapine fumarate equivalent to 25 mg quetiapine. Each 50 mg tablet contains 57.5 mg of quetiapine fumarate equivalent to 50 mg quetiapine. Each 100 mg tablet contains 115.0 mg of quetiapine fumarate equivalent to 100 mg quetiapine. Each 200 mg tablet contains 230.0 mg of quetiapine fumarate equivalent to 200 mg quetiapine. Each 300 mg tablet contains 345.0 mg of quetiapine fumarate equivalent to 300 mg quetiapine. Each 400 mg tablet contains 460.0 mg of quetiapine fumarate equivalent to 400 mg quetiapine.

Each tablet meets the requirements of the Test 3 Dissolution in the USP monograph for Quetiapine Tablets USP.
Adult degenerative scoliosis (ADS) is the most common spinal deformity in the elderly, and the severe patients need surgical treatment. The elderly are often complicated with many medical diseases and the perioperative risk is high, so minimally invasive surgery is a new choice for spinal surgeons to treat ADS. Modified lateral lumbar interbody fusion (CLIF) is an new modified spinal minimally invasive interbody fusion technique in the investigator's department. The results of preliminary studies showed that it has the advantages of less trauma, short operation time and fewer complications, and the clinical and imaging outcome are remarkable. Therefore, the present study aims to establish a multicenter, large sample prospective randomized controlled study to explore the technical advantages and surgical indications of the new technique in the treatment of ADS by comparing with the traditional posterior spinal interbody fusion; (2) to compare the postoperative clinical and imaging results and analyze the surgical complications and preventive measures; (3) to establish a long-term follow-up to further quantify the clinical and imaging outcome of the new technique. Therefore, this study will further verify the safety and effectiveness of the CLIF in the treatment of ADS on the basis of previous studies, and provide a new clinical approach for minimally invasive treatment of ADS.
PROBLEM TO BE SOLVED: To obtain a medicine-containing substance capable of being simply and readily taken from the mouth without using water, etc. SOLUTION: Oral medicines 3 to 5 are wrapped in an edible and drinkable soft substance 8 so as to be readily taken from the mouth. Medicines for plural times which are divided into parts each in an amount for one dose are integrally formed and provided with at least one of fragrance, coloring and taste to give the objective medicine containing substance. The edible and drinkable substance is harmless to a human body and includes an organic substance as well as foods and beverages. For example, a substance made from agar, gelatin, jelly or starch may be used. Preferably, the substance is readily taken from the mouth, soft and good in passing the throat. The medicine-containing substance is provided with fragrance, coloring, taste, etc.
Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score \>6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of Digitalis lanata. The term “digitalis” is used to designate the whole group of glycosides. The glycosides are composed of 2 portions: a sugar and a cardenolide (hence “glycosides”). 

  


Digoxin is described chemically as (3β,5β,12β)-3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-­(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-­hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide. Its molecular formula is C41H64O14, its molecular weight is 780.95, and its structural formula is:  


Digoxin USP exists as clear to white, crystals or white crystalline powder that melt with decomposition above 230°C. The drug is practically insoluble in water, soluble in a mixture of equal volumes of methanol and methylene chloride, slightly soluble in ethanol (96 per cent). 

Digoxin tablets, USP are supplied as 62.5 mcg (unscored), 125 mcg (scored) and 250 mcg (scored) tablets for oral administration. Each tablet contains the labeled amount of digoxin USP and the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate and pregelatinized starch (maize). In addition the 62.5 mcg tablets contain FD & C Yellow No. 6 Lake.  
  
FDA approved dissolution test specifications differ from USP.
BACKGROUND: This study sought to answer the following questions: (1) Are there differences in knowledge on time to treatment (TTT) between stroke, myocardial infarction (MI), and hip fractures in the general population? (2) Are there differences in condition-specific knowledge across these conditions? (3) Are there underlying demographic factors that may contribute to differences in hip fracture-specific knowledge?
MATERIALS AND METHODS: This was a cross-sectional cohort analysis. Participants were acquired using an online survey distribution platform, Amazon Mechanical Turk (MTurk). Individuals older than 18 years with English fluency and literacy were included. A total of 913 participants who completed a survey with questions on TTT knowledge, condition-specific knowledge, history of hip fracture, and demographics were recruited.
RESULTS: On comparing TTT knowledge, the MI mean score was 36.92% higher than that of hip fractures (P<.0001). On comparing condition-specific knowledge, the MI-specific mean score was 8.24% higher than that of hip fractures (P<.0001). Hip fracture knowledge was associated with demographic factors. Asian and Black participants and participants with Medicaid or Medicare as their primary insurance type were associated with significantly lower hip fracture knowledge.
CONCLUSION: Hip fracture knowledge was significantly lower than MI knowledge in the study population. Just as professional societies have invested resources in public education campaigns on the importance of TTT for stroke and MI, public education campaigns on the importance of TTT for hip fractures may support earlier TTT for populations vulnerable to delays (Asian and Black). [Orthopedics. 2024;47(6):377-383.].
The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
In a magnetic resonance a method and apparatus to generate images by a parallel acquisition technique, a first echo train is generated after a first excitation pulse, wherein the first echo train sufficiently densely scans a segment of k-space to be scanned for an acquisition of coil calibration data. Coil calibration data are acquired by means of the first echo train after the first excitation pulse. The acquired coil calibration data are stored in a coil calibration data set. A second echo train is generated after a second excitation pulse, wherein the second echo train undersamples a segment of k-space to be scanned for an acquisition of image data. Image data are acquired by means of the second echo train after the second excitation pulse. The acquired image data are stored in an incomplete image data set. An image data set is generated by substituting data missing in the incomplete image data set due to the undersampling by means of a selected PAT reconstruction technique using the coil calibration data. The first echo train and the second echo train are generated by an identical sequence technique such that each echo train has a series of echoes, with a time interval of the echoes of a series of the first echo train being shorter than a time interval of the echoes of a series of the second echo train.